B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice.
about
Type I interferon blockade in systemic lupus erythematosus: where do we stand?Intracellular nucleic acid sensors and autoimmunityModelling clinical systemic lupus erythematosus: similarities, differences and success storiesInterferon alpha on NZM2328.Lc1R27: enhancing autoimmunity and immune complex-mediated glomerulonephritis without end stage renal failureCurrent and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.Cytokine disturbances in systemic lupus erythematosus.Effect of Leflunomide on the Abnormal Expression of Lipid Rafts and F-Actin in B Lymphocytes from Patients with Systemic Lupus ErythematosusLocal triggering of the ICOS coreceptor by CD11c(+) myeloid cells drives organ inflammation in lupus.The discovery and development of belimumab: the anti-BLyS-lupus connectionDispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice.Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).Epidermal injury promotes nephritis flare in lupus-prone mice.Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed miceDevelopment of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor.Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression.IFNα Inducible Models of Murine SLE.Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to dateInteractions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases.Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?B-lymphocyte signalling abnormalities and lupus immunopathology.Future prospects in biologic therapy for systemic lupus erythematosus.Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.B cells biology in systemic lupus erythematosus-from bench to bedside.Crosstalk between type II NKT cells and T cells leads to spontaneous chronic inflammatory liver disease.HIV-1-Mediated BAFF Secretion in Macrophages Does Not Require Endosomal TLRs, Type-I IFN, and Nef, but Depends on the Cellular Phenotype Status.Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors.Circulating CXCR5+CD4+helper T cells in systemic lupus erythematosus patients share phenotypic properties with germinal center follicular helper T cells and promote antibody production.Profiling of B-Cell Factors and Their Decoy Receptors in Rheumatoid Arthritis: Association With Clinical Features and Treatment Outcomes
P2860
Q26865441-E4BACBD2-F488-46A2-B713-2273A3831567Q26997316-B911E89A-272D-4C46-A05A-D3E11B3EF837Q28074217-8A27061E-46D0-4093-A9D9-50B37F6DA272Q30410652-AA212F94-987F-46C6-B2F8-498752713DFCQ34960458-35698EE0-D927-44DF-8EF9-F00ECDC1B6B9Q35617573-A291CAEF-A010-4C5E-BA61-930696BB4252Q35674006-313E11AE-633A-425B-B7EA-F05F9E880C0CQ35686263-862E8F65-A08C-456D-81C1-643A74DFE76EQ35691272-1CF928E7-9026-42E7-836A-C9E9DE4D5F89Q35798968-5915874D-4068-4CBA-B891-AFAE8CF64338Q36271212-6ED00359-1FB3-48B0-90FE-C8F6F4AAEA66Q36373291-C3AA1458-71C4-4C1A-AA14-349509933679Q36490737-8943A036-18C1-4130-85A0-4B1113893668Q36745567-3FB2CC19-4BFF-4896-8E31-8749219D8E15Q36745815-886BFD02-1AFC-45A8-909B-B4D523F56978Q37210594-CBC7499E-0FF2-4DD4-80DA-29A8771BB6CDQ37709763-53F3ACE7-391E-4CB7-AB18-642E0ACCB59AQ37737549-97BE04DD-3F61-4947-BE4A-046E9DC50300Q38006643-D9BFEC76-6496-49A1-8C6F-17E433FAC187Q38114500-11EEB81C-9E68-4AA3-8D8E-83B9F22860FFQ38135706-C47D9927-F43E-4913-A94F-B8C467A2DFF8Q38187489-5200E820-C556-41E4-9713-91E3E472F60CQ38631964-7D840D70-A429-41AB-A69D-BA70FBCD2665Q38735507-A3093456-7577-46CF-88E3-88F35232C586Q39027389-5B370AAD-EAA2-4E32-AC6E-74395AB71640Q42737499-6C31BE30-4D35-4247-B745-399352F9E4F3Q46536956-30338DD4-B088-4798-BEC5-C871830253ACQ53618640-7A105BFC-2874-4381-914D-14AB8B410F99Q58122908-FDB5C943-BCED-4D22-9D0E-60EB4E5E1D01
P2860
B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
B Cell and BAFF dependence of ...... hematosus-prone NZM 2328 mice.
@ast
B Cell and BAFF dependence of ...... hematosus-prone NZM 2328 mice.
@en
B Cell and BAFF dependence of ...... hematosus-prone NZM 2328 mice.
@nl
type
label
B Cell and BAFF dependence of ...... hematosus-prone NZM 2328 mice.
@ast
B Cell and BAFF dependence of ...... hematosus-prone NZM 2328 mice.
@en
B Cell and BAFF dependence of ...... hematosus-prone NZM 2328 mice.
@nl
prefLabel
B Cell and BAFF dependence of ...... hematosus-prone NZM 2328 mice.
@ast
B Cell and BAFF dependence of ...... hematosus-prone NZM 2328 mice.
@en
B Cell and BAFF dependence of ...... hematosus-prone NZM 2328 mice.
@nl
P2093
P2860
P356
P1476
B Cell and BAFF dependence of ...... hematosus-prone NZM 2328 mice.
@en
P2093
Alexis Mathian
Chaim O Jacob
Chaim Putterman
Michael N Koss
Noam Jacob
Shunhua Guo
Simona Gindea
William Stohl
P2860
P304
P356
10.4049/JIMMUNOL.1000466
P407
P577
2011-03-07T00:00:00Z